Venture-backed Devoted Health seems to be weathering the Medicare Advantage storm, according to an Endpoints News analysis of ...

Pfizer is expanding its multibillion-dollar cost-cutting effort that began in 2023, announcing $1.7 billion in new planned ...

The fate of a small, privately-held biotech’s new drug has been delayed, in what appears to be a sign that broad cuts to the ...

AstraZeneca said it was shutting down a Phase 3 Truqap study in a hard-to-treat form of prostate cancer after an interim ...

Novartis reports strong Q1 2025 with $13.2B in sales, beating forecasts. Key drugs Xolair, Zolgensma, Kisqali exceed ...

In an unlikely partnership between two rivals, Hims & Hers said its members will now be able to get Novo Nordisk’s weight ...

Octagon Therapeutics, led by CEO Isaac Stoner, is shutting down after halting work on B cell immunomodulator and facing ...

As it awaits an FDA approval decision on apitegromab for spinal muscular atrophy, Scholar Rock is reshaping its leadership ...

Vertex Pharmaceuticals, Amgen and Jazz Pharmaceuticals are among companies that received a positive opinion from European ...

Merck's Keytruda shows 27% reduced risk of recurrence/death in head & neck cancer when used before & after surgery, with FDA ...

France’s national public health agency is suspending immunization of adults 65 years and older with Valneva’s chikungunya ...

Globally, approximately 300 million people are grappling with obesity, a complex disease that has a profound impact on a ...